-
Something wrong with this record ?
The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells
V. Navrkalova, L. Sebejova, J. Zemanova, Z. Jaskova, M. Trbusek,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Transcriptional Activation * MeSH
- Ataxia Telangiectasia Mutated Proteins genetics metabolism MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell drug therapy genetics metabolism MeSH
- DNA Breaks, Double-Stranded MeSH
- Histones genetics MeSH
- Humans MeSH
- Tumor Suppressor Protein p53 metabolism MeSH
- Proliferating Cell Nuclear Antigen metabolism MeSH
- Antineoplastic Agents pharmacology therapeutic use MeSH
- Gene Expression Regulation, Leukemic drug effects MeSH
- Signal Transduction * MeSH
- Vidarabine analogs & derivatives pharmacology therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The prognostic role of ATM defects is well documented in chronic lymphocytic leukemia. However, the predictive value of ATM inactivation is much less understood, even in response to common drugs like fludarabine. It has been demonstrated that CLL cells having inactive ATM exhibit defective phosphorylation of its downstream targets after fludarabine treatment. We performed alternative analysis focusing on fludarabine-induced p53 accumulation and induction of p53-downstream genes after artificial ATM inhibition and, in parallel, using cells with endogenous ATM inactivation. We show that after 24h fludarabine exposure: (i) 5 out of 8 ATM-deficient samples (63%) normally accumulated p53 protein, and (ii) all analyzed ATM-deficient samples (n = 7) manifested clear induction of p21, PUMA, BAX, and GADD45 genes. In all experiments, doxorubicin was used as a confined ATM inductor and confirmed effective ATM inactivation. In conclusion, CLL cells lacking functional ATM appear to have normal response to fludarabine regarding the p53 pathway activation.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14050952
- 003
- CZ-PrNML
- 005
- 20140410121158.0
- 007
- ta
- 008
- 140401s2013 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/10428194.2013.796056 $2 doi
- 035 __
- $a (PubMed)23808769
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Navrkalova, Veronika
- 245 14
- $a The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells / $c V. Navrkalova, L. Sebejova, J. Zemanova, Z. Jaskova, M. Trbusek,
- 520 9_
- $a The prognostic role of ATM defects is well documented in chronic lymphocytic leukemia. However, the predictive value of ATM inactivation is much less understood, even in response to common drugs like fludarabine. It has been demonstrated that CLL cells having inactive ATM exhibit defective phosphorylation of its downstream targets after fludarabine treatment. We performed alternative analysis focusing on fludarabine-induced p53 accumulation and induction of p53-downstream genes after artificial ATM inhibition and, in parallel, using cells with endogenous ATM inactivation. We show that after 24h fludarabine exposure: (i) 5 out of 8 ATM-deficient samples (63%) normally accumulated p53 protein, and (ii) all analyzed ATM-deficient samples (n = 7) manifested clear induction of p21, PUMA, BAX, and GADD45 genes. In all experiments, doxorubicin was used as a confined ATM inductor and confirmed effective ATM inactivation. In conclusion, CLL cells lacking functional ATM appear to have normal response to fludarabine regarding the p53 pathway activation.
- 650 _2
- $a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a ATM protein $x genetika $x metabolismus $7 D064007
- 650 _2
- $a dvouřetězcové zlomy DNA $7 D053903
- 650 _2
- $a regulace genové exprese u leukemie $x účinky léků $7 D015973
- 650 _2
- $a histony $x genetika $7 D006657
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x farmakoterapie $x genetika $x metabolismus $7 D015451
- 650 _2
- $a proliferační antigen buněčného jádra $x metabolismus $7 D018809
- 650 12
- $a signální transdukce $7 D015398
- 650 12
- $a aktivace transkripce $7 D015533
- 650 _2
- $a nádorový supresorový protein p53 $x metabolismus $7 D016159
- 650 _2
- $a vidarabin $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D014740
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Sebejova, Ludmila $u -
- 700 1_
- $a Zemanova, Jana $u -
- 700 1_
- $a Jaskova, Zuzana $u -
- 700 1_
- $a Trbusek, Martin $u -
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 54, č. 8 (2013), s. 1840-3
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23808769 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140401 $b ABA008
- 991 __
- $a 20140410121248 $b ABA008
- 999 __
- $a ok $b bmc $g 1018088 $s 849532
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 54 $c 8 $d 1840-3 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- LZP __
- $a Pubmed-20140401
